SEC Company Response from Cocrystal Pharma, Inc. (COCP) (CIK 0001412486) (COCP) — May 12, 2020
Cocrystal Pharma, Inc. (COCP) (CIK 0001412486)
Date: May 12, 2020 · CIK: 0001412486 · Accession: 0001493152-20-008313
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237738
Letter
Via EDGAR Division of Corporation Finance Securities and Exchange Commission Attention: Mr. Tim Buchmiller Re: Cocrystal Pharma, Inc. Registration Statement on Form S-3 File No. 333-237738
Dear Mr. Buchmiller:
In accordance with Rule 461 promulgated pursuant to the Securities Act of 1933, Cocrystal Pharma, Inc. (the “Company”) is hereby requesting that the effective date of the above-referenced Registration Statement be accelerated so that the same will become effective at 4:00 p.m. on May 13, 2020, or as soon thereafter as may be practicable.
If you have any questions regarding this request, please contact Michael Harris, our legal counsel at (561) 644-2222.
Very truly yours,
/s/ James Martin
Show Raw Text
CORRESP
1
filename1.htm
Cocrystal
Pharma, Inc.
9805
North Creek Parkway
Bothell,
Washington
May
12, 2020
Via
EDGAR
Division
of Corporation Finance
Securities
and Exchange Commission
100
F Street, N.E.
Washington,
D. C. 20549
Attention:
Mr. Tim Buchmiller
Re:
Cocrystal
Pharma, Inc.
Registration
Statement on Form S-3
File
No. 333-237738
Dear
Mr. Buchmiller:
In
accordance with Rule 461 promulgated pursuant to the Securities Act of 1933, Cocrystal Pharma, Inc. (the “Company”)
is hereby requesting that the effective date of the above-referenced Registration Statement be accelerated so that the same will
become effective at 4:00 p.m. on May 13, 2020, or as soon thereafter as may be practicable.
If
you have any questions regarding this request, please contact Michael Harris, our legal counsel at (561) 644-2222.
Very truly yours,
/s/ James Martin
James Martin
Chief Financial Officer
cc:
Michael
D. Harris, Esq.
Constantine
Christakis, Esq.